Institute Of Cancer Research, United Kingdom

This trial is testing two experimental drugs, avutometinib and defactinib, given together or with a standard chemotherapy (temozolomide) for people with high-grade brain tumours like glioblastoma. The study has two phases: first, to check safety and find the right dose, and secon…

This study tests whether injecting a very dilute hydrogen peroxide solution directly into breast tumors can make standard radiotherapy more effective. Researchers are enrolling 184 adults with locally advanced or recurrent breast cancer. Participants will receive injections twice…

This study tests whether adding a combination of antibiotics to the standard drug enzalutamide can help treat metastatic castration-resistant prostate cancer (mCRPC), a type of advanced prostate cancer that no longer responds to hormone therapy. About 39 participants will receive…

This study is for men with a type of advanced prostate cancer that has spread and no longer responds to standard hormone therapy. It tests whether adding a new drug called SX-682 to the existing drug apalutamide is safe and can shrink tumors or slow the cancer. About 78 men will …

This early-phase study tests a new drug, ASTX660, combined with the immunotherapy pembrolizumab in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if this combination can make cancer cells more visible to the immune system…

This study tests a new drug called paxalisib combined with standard chemotherapy (temozolomide) in people with aggressive brain tumours like glioblastoma. The goal is to see if the combination is safe and can help control the tumour for longer. About 64 adults with newly diagnose…

This study compares a new PET-CT scan (FCH-PET-CT) to standard imaging (bone scan and MRI/CT) to see which better finds cancer that has spread outside the pelvis in men with prostate cancer and specific DNA repair gene mutations. About 50 men with these mutations will be enrolled…

This study follows 200 men with low-risk prostate cancer who are on active surveillance (monitoring instead of immediate treatment). Researchers want to see if men with a higher genetic risk for prostate cancer are more likely to have their cancer progress over time. The goal is …

This study follows over 4,000 men with prostate cancer, some with rare gene mutations (BRCA1, BRCA2, HOXB13, Lynch Syndrome) and some without. Researchers will track their treatment results and survival over time. The goal is to learn whether these mutations affect how the diseas…

This study is testing a new saliva-based DNA test called i4i PRODICT® that looks for both common and rare genetic changes to estimate a man's future risk of prostate cancer. The study will enroll 1,000 men aged 40-55 from Black African/Caribbean, South Asian, and White background…

This study looks at whether a genetic test can help predict prostate cancer risk in men who have or are at high risk for the disease. Researchers will analyze DNA from 3000 men to find rare and common genetic changes linked to prostate cancer. The goal is to see if this informati…